ABD-320 / Abdera Therap - LARVOL DELTA

111In/225Ac-ABD320, a novel 5T4-targeted radiopharmaceutical with favorable tumor-to-normal tissue biodistribution and single-dose efficacy in preclinical cancer models (AACR 2025) - "Within-mouse dosimetry estimates a tumor inferred dose of 50 to 80 Gy corresponding to efficacious doses of 225 Ac-ABD320. In conclusion, ABD320, which employs a novel VHH-binder and linker-chelator, selectively and preferentially delivers radionuclides to 5T4 expressing tumors, demonstrates potent anticancer activity and is a promising candidate for further development."

Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • TPBG

Abdera Therapeutics to Present Key Updates on its Radiopharmaceutical Development Pipeline at the 2025 American Association for Cancer Research (AACR) Annual Meeting (Businesswire) - "Abdera Therapeutics Inc...announced two upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting, being held from April 25 – 30, 2025 in Chicago, IL. These include: (1) a poster presentation of Abdera’s ongoing Phase 1 clinical trial for ABD-147, a DLL3-targeting radiopharmaceutical, and (2) preclinical data on ABD-320, a 5T4-targeting radiopharmaceutical and Abdera’s second development program."

P1 data • Preclinical • Neuroendocrine Carcinoma • Small Cell Lung Cancer

Abdera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (Businesswire) - "Abdera Therapeutics Inc...announced that Lori Lyons-Williams, president and chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. PT in San Francisco, CA....Ms. Lyons will detail the company’s progress including the recently initiated first-in-human Phase 1 clinical trial evaluating ABD-147 for the treatment of small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). The company also plans to share, for the first time publicly, preclinical data for ABD-320, which is currently in IND-enabling studies, and provide an update on expanded radiotherapeutic capabilities."

Preclinical • Trial status • Neuroendocrine Tumor • Small Cell Lung Cancer